BeyondSpring announces positive phase 3 study analysis of Plinabulin
BeyondSpring announced the Phase 3 portion of its pivotal Study 105, evaluating its lead asset, Plinabulin, in the 105 enrolled patients treated with docetaxel chemotherapy, has met its primary endpoint of non-inferiority versus Neulasta®. December 06, 2018